ClinicalTrials.gg
RecruitingNCT05908214MnHyperexUpdated Nov 28, 2023

The Application of Wide Pulse High Frequency Neuromuscular Electrical Stimulation in Disorders Associated With Motoneuron Hyperexcitability

An interventional study of wide pulse high frequency neuromuscular electrical stimulation training in Stroke, Cramp and Restless Legs Syndrome, sponsored by University of Lausanne. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-28.

Sponsored by University of Lausanne · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 216 studies in Stroke with a site in Switzerland — 46 open to participants now, 60 under way, 6 of them phase 3. Stroke · Switzerland.

Planned enrollment
62nd of 147
110 · median 79
Started
2023
with 8 others
No phase
95 of 216
24 open now
Primary completion
2025-12
later than 10 of 59 live
Registered
175th of 216
by date

Among the 216 studies in Stroke with a site in Switzerland, this one is the 62nd largest by planned enrollment of the 147 interventional ones that give a count, is one of 9 that started in 2023, is one of 95 with no phase, reaches primary completion later than 10 of the 59 other live ones, and was the 175th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

46 of the 216 studies in Stroke with a site in Switzerland are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Stroke with a site in Switzerland, or all of them as a file.
02

Study summary

In the present project, the investigators aim at proposing innovative ways of investigating spinal motoneuron hyperexcitability to counteract the associated impairments by using wide pulse high frequency neuromuscular electrical stimulation (WPHF NMES) in various populations. The investigators will use WPHF NMES contractions as a model to gain insights into the mechanisms underlying muscle cramps, restless legs syndrome or stroke-induced spasticity as there is evidence that they share common underlying mechanisms. The investigators will then use WPHF NMES as a training modality to improve plantar flexor neuromuscular function in stroke patients by taking advantage of their motoneuronal hyperexcitability.

03

Conditions studied

  • Stroke
  • Cramp
  • Restless Legs Syndrome
  • Healthy Volunteers

Keywords

  • muscle strength
  • persistent inward current
  • training
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

STROKE PATIENTS:

  • Diagnosis of first-ever stroke (ischemic or hemorrhagic) with unilateral motor deficits from at least 6 months. Stroke will have to be confirmed from medical records and/or radiological imaging (CT scan or MRI)
  • Inadequate ankle control during gait defined as ankle dorsiflexion less than 5° during stance phase and 0° during swing phase; 0° = ankle neutral position)
  • Passive range of motion of ankle dorsiflexion at least to neutral position
  • Ability to walk at least 10 m with or without assistive devices
  • Spasticity at the triceps surae (either soleus and/or gastrocnemii) considered as a Modified Ashworth Sore ≥1
  • Being available for the study period and willing to participate
  • No to neuromuscular electrical stimulation

Contraindications for stroke patients:

  • Surface sensory loss of affected lower leg (defined as incapacity to feel the 60-g touch using the Semmes-Weinstein monofilament test)
  • Patients unable to understand indications or to provide
  • A history of orthopedic or other neurological disorders affecting walking function
  • A history of surgery to correct drop foot (ankle fixation)
  • Patients under antispastic medication (baclofen, tizanidine, tolperisone, benzodiazepines, dantrolene or botulinum toxin to the plantar flexor muscles in the last 6 months).

PEOPLE PRONE TO MUSCLE CRAMPS:

  • Reporting nocturnal muscle cramps (the assessment will be done through a questionnaire)
  • Not being treated for muscle cramps
  • Being available for the study period and willing to participate
  • No contraindication to neuromuscular electrical stimulation

PATIENTS WITH RESTLESS LEGS SYNDROME:

To be included in the study, RLS patients will have to satisfy the Diagnostic criteria for RLS published by the International Restless Legs Syndrome StudyGroup (IRLSSG). All five key clinical features are required for the diagnosis:

  • An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs. Sometimes the urge to move is present without the uncomfortable sensations, and sometimes the arms or other body parts are involved in addition to the legs.
  • The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.
  • The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.
  • The urge to move or unpleasant sensations are worse in the evening or night than during the day, or only occur in the evening or night. When symptoms are severe, the worsening at night may not be noticeable but must have been previously present.
  • Symptoms are not solely accounted for by another medical or behavioral condition, such as leg cramps or habitual foot tapping.
  • No contraindication to neuromuscular electrical stimulation

They will also have to satisfy the following criteria:

  • Diagnosis of primary RLS corresponding to:

    1. The presence of periodic limb movements
    2. A dopaminergic treatment response
    3. The presence of RLS in first-degree relatives
    4. A lack of profound daytime sleepiness
  • Being available for the study period and willing to participate

HEALTHY PARTICIPANTS:

  • No neurological disease
  • No contraindication to neuromuscular electrical stimulation
  • Being available for the study period and willing to participate
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Stroke patients - training group

    Participants in this group will take part in a 6-week WPHF NMES training period and plantar flexor neuromuscular function will be assessed before and after training.

    Other: wide pulse high frequency neuromuscular electrical stimulation training

  • No intervention
    stroke patients - control group

    Participants in this group will keep their daily life activities for 6 weeks and plantar flexor neuromuscular function will be assessed before and after training.

Interventions

  • Otherwide pulse high frequency neuromuscular electrical stimulation training

    Plantar flexors will be stimulated with wide pulse high frequency neuromuscular electrical stimulation 3 times a week for 6 weeks

06

What researchers measure

Primary outcomes

  1. Change in maximal voluntary contraction force

    Change from baseline maximal voluntary contraction force after the six-week training period in stroke patients

    Time frame: through study completion, an average of 8 weeks

  2. Change in NMES-evoked force

    Change from baseline NMES-evoked force after the six-week training period

    Time frame: through study completion, an average of 8 weeks

  3. NMES-evoked force

    Comparison of NMES-evoked force in plantar flexor muscles between patients (prone to cramps or restless legs) and healthy volunteers

    Time frame: through study completion, an average of 2 weeks

  4. Change in estimates of persistent inward current (Delta F assessed with high-density surface electromyography and/ or the torque measured during vibration after the last bout of NMES)

    Change from baseline estimates of persistent inward current after the six-week training period in stroke patients

    Time frame: through study completion, an average of 8 weeks

  5. Estimates of persistent inward current (Delta F assessed with high-density surface electromyography and/ or the torque measured during vibration after the last bout of NMES)

    comparison of estimates of persistent inward current strength in plantar flexor muscles between patients (prone to cramps or restless legs) and healthy volunteers

    Time frame: through study completion, an average of 8 weeks

Secondary outcomes

  1. Change in voluntary activation level and contractile properties of the plantar flexor muscles

    Change from baseline voluntary activation level and contractile properties of the plantar flexor muscles after the six-week training period in stroke patients

    Time frame: through study completion, an average of 8 weeks

  2. voluntary activation level and contractile properties of the plantar flexor muscles

    comparison of voluntary activation level and contractile properties of the plantar flexor muscles between patients (prone to cramps or restless legs) and healthy volunteers

    Time frame: through study completion, an average of 2 weeks

  3. change in spasticity at the ankle joint level for stroke patients

    Change from baseline Ashworth scale score (minimal score 0, maximal score 4, a higher score means a worst outcome) after the six-week training period in stroke patients

    Time frame: through study completion, an average of 8 weeks

  4. 10-m walking test (s)

    functional test

    Time frame: through study completion, an average of 8 weeks

  5. 6-min walking test (m)

    functional test

    Time frame: through study completion, an average of 8 weeks

  6. time up and go test (s)

    functional test

    Time frame: through study completion, an average of 8 weeks

  7. Change in spinal excitability in stroke patients

    change from baseline soleus Hoffmann reflex amplitude after the six-week training period in stroke patients

    Time frame: through study completion, an average of 8 weeks

  8. Spinal excitability

    comparison of soleus Hoffmann reflex amplitude between patients (prone to cramps or restless legs) and healthy volunteers

    Time frame: through study completion, an average of 2 weeks

  9. Cramp threshold frequency (CTF) for cramp-prone individuals

    comparison between participants reporting muscle cramps and healthy volunteers

    Time frame: through study completion, an average of 2 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2025, 26 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 26 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2023
First posted
Jun 18, 2023
StartActual
Oct 1, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Nov 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05908214
Lead sponsor
University of Lausanne
Collaborators
Swiss National Science Foundation
Responsible party
Nicolas Place (Professor, University of Lausanne) — Principal investigator
First posted
Jun 18, 2023
Start date
Oct 1, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 28, 2023

Study contacts

Nicolas Place, PhD
Contact
nicolas.place@unil.ch
+41216923806

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion